STAT+: Many patient, consumer reps on FDA advisory panels have ties to groups funded by pharma, analysis finds

Nearly 40% of Food and Drug Administration advisory committee meetings held over a recent 20-year period included either a patient or consumer representative with active ties to an advocacy group funded by pharmaceutical companies, according to a new analysis. And for several committees, the number of such reps exceeded 50%. In addition, more than one in 10 advisory committee meetings included a rep who was affiliated with an organization that received funding from the drugmaker whose medicine w...